In August 2020, Zhejiang Boxiao Biopharmaceutical Co., Ltd. was set up in Xin Deng, Fuyang District, National Economic and Technological Development Park. It was founded by a group of seasoned pharmaceutical specialists with decades of pharma background and rich practical experiences. An innovative biopharmaceutical company with a high degree of integration of Research, Production and Sales.
聽
The BXBP (Boxiao Biopharmaceutical) aims at the big health industry. The national and military strategies and un-met clinical needs of the people. Under the framework of "specialization, refinement, specialness and innovation", BXBP actively seeks differentiation and import substitution; focuses on the indication: anti-pain, cerebral infarction, myocardial infarction, Gout, high uric acid, prenatal and postnatal care, adhering to the spirit of "innovation and entrepreneurship, pure original motivation, forging ahead", and ingeniously develop good medicines.
聽
At present, the BXBP has completed the construction of a platform from technology and the diversified layout of derivative products from the platform. Based on the strategic goal of the integration of "characteristic raw materials (intermediates) + special preparations" from Chinese domestic market and extend to the global market, it provides diversified services for multiple subdivided therapeutic fields in the pharmaceutical industry, and provides innovative drugs and professional solutions for the public solutions, becoming one of the most valuable and trustworthy biopharmaceutical companies in China.